Rani Therapeutics Holdings Inc. (RANI), a clinical-stage biotherapeutics company, on Tuesday announced pricing of a registered direct offering worth $20 million.
Following the announcement, shares fell by 10% on Tuesday.
The company entered a securities purchase agreement led by a sovereign wealth fund and is offering 12,476,637 shares of Class A common stock at $1.07 per share.
The company is also issuing pre-funded warrants to 6,214,953 shares of Class A common stock at a purchase price of $1.0699 per pre-funded warrant.
The gross proceeds from the offering are estimated to be $20 million.
The offering is expected to close on May 27, 2026.
RANI is currently trading at $0.95, down 10.93%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.